Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-05-14
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with vitiligo.